ImmunoGen Message Board - Msg: 15163763

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RJMC who wrote (3798)	1/11/2001 11:00:34 AM
From: Gary Mohilner	Read Replies (1) of 5665

Bob, No way of telling what the criteria would be, but the analyst for AHH mentions a milestone for efficacy expected this quarter in the following link. extranet.ahh.com I can only guess that the 50% reduction would be in a specified number of patients, what's important is the analyst's mention of this milestone is added validation that such a milestone exists. The announcement of meeting the milestone would say efficacy loud and clear before the ASCO meeting, a lot of ASCO attendees would be checking out the presentations to learn the details of what's happening in the trial. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next